CIK 0001650648 · Non-accelerated filer<br>Smaller reporting company
4D Molecular Therapeutics, Inc.
Sign in to watch- Ticker
- FDMT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473506994
- Phone
- 5105052680
- Business address
- 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
- Former names
- 4D Molecular Therapeutics Inc., 4D Molecular Therapeutics Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,724,648
- in 7 filings, $2.7M under 10b5-1 plans
Net −$2,724,648. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-08 | Bizily Scott Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,996 | 23,004 | ||
| 2024-02-08 | Kirn David Chief Executive Officer | Sale 10b5-1 | −92,001 | $27.13 | $2.5M | 1,059,153 |
| 2024-02-05 | Kim Robert Young Chief Medical Officer | Option exercise 10b5-1 | +12,000 | $18.66 | $224K | 13,595 |
| 2024-02-05 | Kim Robert Young Chief Medical Officer | Sale 10b5-1 | −12,000 | $30.05 | $361K | 1,595 |
| 2024-02-05 | Kim Robert Young Chief Medical Officer | Option exercise 10b5-1 | +6,000 | $15.78 | $95K | 7,595 |
| 2024-02-05 | Kim Robert Young Chief Medical Officer | Sale 10b5-1 | −6,000 | $30.05 | $180K | 1,595 |
| 2024-02-05 | Kim Robert Young Chief Medical Officer | Option exercise 10b5-1 | +6,000 | $8.04 | $48K | 7,595 |
| 2024-02-05 | Kim Robert Young Chief Medical Officer | Sale 10b5-1 | −6,000 | $30.05 | $180K | 1,595 |
| 2024-02-05 | Kim Robert Young Chief Medical Officer | Sale 10b5-1 | −552 | $30.05 | $17K | 1,043 |
| 2024-02-05 | Kim Robert Young Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,000 | 138,000 | ||
| 2024-02-05 | Kim Robert Young Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 64,000 | ||
| 2024-02-05 | Kim Robert Young Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 54,000 | ||
| 2024-01-23 | Kirn David Chief Executive Officer | Sale | −5,696 | $18.41 | $105K | 1,151,154 |
| 2024-01-05 | Kirn David Chief Executive Officer | Sale 10b5-1 | −28,104 | $19.56 | $550K | 1,156,983 |
| 2024-01-05 | Kirn David Chief Executive Officer | Sale 10b5-1 | −133 | $20.11 | $3K | 1,156,850 |
| 2024-01-04 | Kirn David Chief Executive Officer | Sale 10b5-1 | −40,732 | $20.31 | $827K | 1,185,087 |
| 2024-01-04 | VIKING GLOBAL INVESTORS LP 10% owner | Sale | −540,000 | $19.53 | $10.5M | 4,247,914 |
| 2023-12-18 | Kirn David Chief Executive Officer | Sale 10b5-1 | −4,702 | $18.13 | $85K | 1,225,819 |
| 2023-12-15 | Kirn David Chief Executive Officer | Sale 10b5-1 | −28,632 | $17.27 | $494K | 1,230,521 |
| 2023-12-11 | Mehra Uneek See Remarks | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 |
Page 10 of 16 · 319 trades